Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 02, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,690,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,115.88 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.07% of total voting rights).
- Shares in Issue: 5,336,131,009 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,690,000 shares purchased on June 02, 2008. This transaction increased the proportion of Treasury shares held by the company to 9.07% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,336,131,009) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the total voting rights structure.
- Review the Annual General Meeting minutes from May 21, 2008, to understand the full scope of the share buyback authority utilized.